NCT05677711Completed
Safety and Efficacy of the Ultimaster Stent
A Prospective, Observational Study of the Real World Safety and Effectiveness of the Ultimaster Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions in All-comer Patients (MASTER Trial)
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis. Ultimaster stent (Ultimaster, Terumo Corporation, Tokyo, Japan) are thin strut, silorimus-eluting, biodegradable copolymer to completely degrade over 3-4 months.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 204 (actual)
- First submitted
- 12 Dec 2022
- Start date
- 20 Jul 2021
- Primary completion date
- 24 Sept 2024
- Lead sponsor
- Yonsei University
- Diseases
- Coronary artery disease
- NCT number
- NCT05677711
What you commit to
- Study type: Observational
- Participants enrolled: 204
- From 20 Jul 2021 to the primary completion date, 24 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, prasugrel, ticagrelor
Other
- Life expectancy within 1 year
- If other researchers judge that it is inappropriate to participate in this study
Who the study is looking for
- Age 19 or older
- Clinical evidence of coronary artery disease, including asymptomatic ischemia, stable angina, and acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction)
- No restrictions on the number of blood vessels, number of lesions, and length of lesions
- Those who voluntarily gave written consent to participate in this clinical study
Age in the registry: 19 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yongin Severance Hospital Coordinator of this site? Confirm its status | Yŏngin | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.